UFLEX NSE filing

UFLEX Q2 FY27 Earnings Call Transcript Released

The RealCase readHigh impact Positive

UFLEX Limited released its Q2 FY27 earnings call transcript. The company reported a 26% YoY consolidated revenue growth to ₹48,694 million and a 689% YoY net profit increase to ₹2,106 million. Normalized EBITDA grew 95% to ₹7,588 million. Management expressed confidence in achieving 30% revenue and EBITDA growth for FY27, with a focus on increasing capacity utilization and expanding value-added product segments.

Why it matters

The detailed financial performance, growth outlook, management commentary on strategic initiatives (like expansion into aseptic packaging and value-added products), and deleveraging strategy are all material factors that would significantly impact investor perception and valuation.

The market read

The company reported strong year-on-year growth in revenue, EBITDA, and net profit, with management expressing confidence in future growth targets despite a challenging environment. The deleveraging efforts and strategic focus on high-margin products also contribute to a positive sentiment.

UFLEX Limited has released the transcript of its earnings conference call held on November 16, 2026. The call, hosted by Arihant Capital Markets Limited, featured insights from Mr. Arun Kumar Sharma (President, Finance and Accounts and Group CFO) and Mr. Surajit Pal (Vice President, Head of Investor Relations).

During the call, Mr. Sharma highlighted UFLEX's strong performance over the last three consecutive quarters, with momentum carrying from Q4 FY26 into Q1 and Q2 FY27. He noted robust year-on-year revenue growth and profitability expansion, driven by a diversified global footprint and a resilient business model, despite a challenging operating environment characterized by elevated inflation, high crude and energy prices, rising logistics costs, and supply chain disruptions.

Key financial highlights for Q2 FY27 included a 26% year-on-year consolidated revenue growth to ₹48,694 million (US$584.3 million), with incremental revenue of ₹10,084 million. Normalized EBITDA increased by 95% year-on-year to ₹7,588 million, with margins expanding by 550 basis points to 15.6%. Overseas operations contributed 56% of the incremental revenue and 74% of the incremental normalized EBITDA. Consolidated net profit after tax grew 689% year-on-year to ₹2,106 million, with net profit margin expanding by 360 basis points to 4.3%.

Total sales volume increased by 1.5% year-on-year to 163,532 metric tons. Packaging films accounted for 78.9% of total volume, growing 3% year-on-year, while the packaging business volume declined 3.9% due to a strategic shift towards higher-margin flexible packaging. Capital expenditure of ₹5,689 million was incurred in Q2 FY27 for projects including an aseptic packaging facility in Egypt, a recycling unit in Noida, and a BOPP line in Dharwad.

The company remains confident in achieving its guided revenue and EBITDA growth of around 30% for the full year FY27. H1 FY27 achieved revenue of ₹102,666 million and EBITDA of ₹15,961 million, representing approximately 49%-51% and 60%-62% of full-year targets, respectively. Future growth drivers include the ramp-up of new capacities, product mix optimization, and the commissioning of a 12 billion pack aseptic packaging facility in Egypt in H2 FY27.

Management addressed concerns regarding debt, stating that leverage ratios have been brought down from over 4.5 to 3.33 in Q2 FY27, with a target range of 3-3.5 for the end of the financial year. They emphasized a focus on growth while keeping leverage under control, projecting significantly reduced leveraging levels by FY28-29 as new capacities become fully utilized. The Dharwad plant is expected to commence commercial operations mainly in H1 FY28.

Discussions also covered the improvement in profit margins due to increased capacity utilization (around 80%) and the higher margins from overseas operations. The company is strategically shifting towards value-added products, particularly in flexible and aseptic packaging, to enhance profitability. The aseptic packaging plant in Egypt is slated to begin commercial production in H2 FY27, with capacity utilization expected to reach 100% by FY28-29. The company aims for value-added products to constitute 50% of its total topline by FY29.

Filing to action

What to do with a filing like this

UFLEX Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by UFLEX Limited. Read the original for the full detail.

View original filing